
Chloe I Bloom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7796460/publications.pdf Version: 2024-02-01



CHLOFIRIOOM

#	Article	IF	CITATIONS
1	The Immune Response in Tuberculosis. Annual Review of Immunology, 2013, 31, 475-527.	21.8	1,108
2	Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. PLoS ONE, 2013, 8, e70630.	2.5	254
3	Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy. PLoS ONE, 2012, 7, e46191.	2.5	190
4	Exacerbation risk and characterisation of the UK's asthma population from infants to old age. Thorax, 2018, 73, 313-320.	5.6	123
5	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 699-711.	10.7	122
6	Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. Nature Immunology, 2018, 19, 625-635.	14.5	119
7	HIV–tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. Nature Communications, 2015, 6, 8451.	12.8	81
8	The Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra-Pulmonary and Pulmonary Tuberculosis. PLoS ONE, 2016, 11, e0162220.	2.5	81
9	The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130427.	4.0	75
10	Low uptake of palliative care for COPD patients within primary care in the UK. European Respiratory Journal, 2018, 51, 1701879.	6.7	66
11	Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Clobal Program. Advances in Therapy, 2020, 37, 4190-4208.	2.9	66
12	Exacerbation Patterns in Adults with Asthma in England. A Population-based Study. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 446-453.	5.6	63
13	A 380-gene meta-signature of active tuberculosis compared with healthy controls. European Respiratory Journal, 2016, 47, 1873-1876.	6.7	51
14	Changing prevalence of current asthma and inhaled corticosteroid treatment inÂthe UK: population-based cohort 2006–2016. European Respiratory Journal, 2019, 53, 1802130.	6.7	50
15	Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 36-45.	5.6	42
16	Systems approaches to studying the immune response in tuberculosis. Current Opinion in Immunology, 2013, 25, 579-587.	5.5	41
17	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015. European Heart Journal, 2020, 41, 1636-1649.	2.2	36
18	Burden of preschool wheeze and progression to asthma in the UK: Population-based cohort 2007 to 2017. Journal of Allergy and Clinical Immunology, 2021, 147, 1949-1958.	2.9	30

Chloe I Bloom

#	Article	IF	CITATIONS
19	Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respiratory Research, 2020, 21, 54.	3.6	28
20	<p>Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016</p> . International Journal of COPD, 2019, Volume 14, 279-287.	2.3	27
21	Changing causes of death for patients with chronic respiratory disease in England, 2005-2015. Thorax, 2019, 74, 483-491.	5.6	26
22	Accelerated FEV ₁ decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. European Respiratory Journal, 2021, 57, 2000918.	6.7	24
23	Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax, 2019, 74, 1078-1086.	5.6	22
24	Predicting COPD 1-year mortality using prognostic predictors routinely measured in primary care. BMC Medicine, 2019, 17, 73.	5.5	19
25	Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 117-124.	2.9	19
26	Health and cost impact of stepping down asthma medication for UK patients, 2001–2017: A population-based observational study. PLoS Medicine, 2020, 17, e1003145.	8.4	19
27	Identification of the Key Differential Transcriptional Responses of Human Whole Blood Following TLR2 or TLR4 Ligation In-Vitro. PLoS ONE, 2014, 9, e97702.	2.5	17
28	Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review. BMJ Open Respiratory Research, 2020, 7, e000756.	3.0	17
29	Nontuberculous mycobacterial disease managed within UK primary care, 2006–2016. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1795-1803.	2.9	16
30	Inadequate specialist care referrals for high-risk asthma patients in the UK: an adult population-based cohort 2006–2017. Journal of Asthma, 2021, 58, 19-25.	1.7	12
31	Temporal Trends in the Incidence of Heart Failure among Patients with Chronic Obstructive Pulmonary Disease and Its Association with Mortality. Annals of the American Thoracic Society, 2020, 17, 939-948.	3.2	11
32	Impact of comorbidities on peak troponin levels and mortality in acute myocardial infarction. Heart, 2020, 106, 677-685.	2.9	10
33	Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study. International Journal of COPD, 2020, Volume 15, 701-710.	2.3	10
34	Clinical profile of predefined asthma phenotypes in a large cohort of UK primary care patients (Clinical Practice Research Datalink). Journal of Asthma and Allergy, 2019, Volume 12, 7-19.	3.4	6
35	First Maintenance Therapy for Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. Pulmonary Therapy, 2022, 8, 57-74.	2.2	5
36	Influence of the first wave of COVID-19 on asthma inhaler prescriptions. Npj Primary Care Respiratory Medicine, 2021, 31, 45.	2.6	4

Chloe I Bloom

#	Article	IF	CITATIONS
37	Hospitalisation and mortality outcomes of patients with comorbid COPD and heart failure: a systematic review protocol. BMJ Open, 2018, 8, e023058.	1.9	3
38	Qualitative Study of Practices and Challenges of Stepping Down Asthma Medication in Primary Care Across the UK. Journal of Asthma and Allergy, 2020, Volume 13, 429-437.	3.4	3
39	Decline in respiratory and cardiac admissions during the COVID $\hat{a} \in 19$ pandemic: What is the role of common respiratory virus infections?. Respirology, 2021, 26, 1010-1011.	2.3	2
40	Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. Pulmonary Therapy, 2022, 8, 75-93.	2.2	2
41	Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease. Journal of Market Access & Health Policy, 2021, 9, 1929757.	1.5	1
42	Considerations for conducting and interpreting long-term follow-up of intervention studies: avoiding spoiled milk. Thorax, 2021, 76, 1067-1068.	5.6	0
43	Title is missing!. , 2020, 17, e1003145.		0
44	Title is missing!. , 2020, 17, e1003145.		0
45	Title is missing!. , 2020, 17, e1003145.		0
46	Title is missing!. , 2020, 17, e1003145.		0
47	Title is missing!. , 2020, 17, e1003145.		Ο